Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-12-13
2008-03-25
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07348316
ABSTRACT:
The invention provides methods for preventing and treating disease involving the use of an anti-endotoxin drug.
REFERENCES:
patent: 4997430 (1991-03-01), Van der Heiden et al.
patent: 5681824 (1997-10-01), Christ et al.
patent: 5756718 (1998-05-01), Kobayashi et al.
patent: 5935938 (1999-08-01), Christ et al.
patent: 0 536 969 (1993-04-01), None
patent: WO 00/41703 (2000-07-01), None
patent: WO 01/37843 (2001-05-01), None
Cooke et al., “LPS Antagonism Reduces Graft-Versus-Host Disease and Preserves Graft-Versus-Leukemia Activity After Experimental Bone Marrow Transplantation,” The Journal of Clinical Investigation 107(12):1581-1589, 2001.
Hawkins et al., “A Novel Class of Endotoxin Receptor Agonists with Simplified Structure, Toll-Like Receptor 4-Dependent Immunostimulatory Action, and Adjuvant Activity,” The Journal of Pharmacology and Experimental Therapeutics 300(2): 655-661, 2002.
Kawata et al., “E5531, a Synthetic Non-Toxic Lipid A Derivative Blocks the Immunobiological Activities of Lipopolysaccharide,” British Journal of Pharmacology 127:853-862, 1999.
Kobayashi et al., “Suppression of Murine Endotoxin Response by E5531, a Novel Synthetic Lipid A Antagonist,” Antimicrobial Agents and Chemotherapy 42(11):2824-2829, 1998.
Lynn et al., “Extended in Vivo Pharmacodynamic Activity of E5564 in Normal Volunteers with Experimental Endotoxemia,” The Journal of Pharmacology and Experimental Therapeutics 308(1):175-181, 2004.
Rose et al., “Consequences of Interaction of a Lipophilic Endotoxin Antagonist with Plasma Lipoproteins,” Antimicrobial Agents and Chemotherapy 44(3):504-510, 2000.
Rossignol et al., “Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers,” Antimicrobial Agents and Chemotherapy 48(9):3233-3240, 2004.
Wasan et al., “Lipoprotein Distribution of a Novel Endotoxin Antagonist, E5531, in Plasma from Human Subjects with Various Lipid Levels,” Antimicrobial Agents and Chemotherapy 43(10):2562-2564, 1999.
DiLea Clifford
Lynn Melvyn
Rossignol Daniel P.
Clark & Elbing LLP
Eisai R&D Management Co., Ltd.
Peselev Elli
LandOfFree
Use of an anti-endotoxin drug in the prevention and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of an anti-endotoxin drug in the prevention and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of an anti-endotoxin drug in the prevention and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3973731